Abstract:In light of the dismal outcome of current treatment and the significant treatment related toxicities in lung cancer, we urgently need markers to individualize our patient’s management. The mutagen sensitivity assay was developed to measure indirectly an individual’s DNA repair capacity to assess susceptibility to tobacco carcinogenesis. Since DNA repair capacity may also predict therapeutic effects and normal tissue repair after chemo/radiotherapy, we hypothesized that mutagen sensitivity may likewise serve as a biomarker for clinical outcome in lung cancer. Patients with lung cancer may have genetic instability unmasked by in vitro exposure of lymphocytes to a mutagen challenge such as bleomycin, a radiomimetic agent. In this study, we explored the role of bleomycin sensitivity in peripheral blood lymphocytes as a predictor of outcome in patients with inoperable stage III non-small cell lung cancer treated with definitive chemo/radiotherapy. 113 patients who were diagnosed with inoperable stage III non-small cell lung cancer at MD Anderson Cancer Center between 1995–2001 were included in this analysis. All patients received definitive radiotherapy with or without chemotherapy. Pre-treatment peripheral blood lymphocytes were collected and cultured for three days. Bleomycin was added for 5 hours and cells were arrested in mitosis using colcemid. Bleomycin sensitivity was measured by counting the mean number of chromatid breaks per cell in 50 metaphases. Patients with an average of more than 1.02 break/cell were considered to exhibit the bleomycin sensitivity phenotype. The data were analyzed using Kaplan-Meier survival function with S-plus 6.1 statistical software. The Log Rank test was used to compare different survivals. Spearman correlation test was used to analyze the correlation between bleomycin sensitivity and complications. High bleomycin sensitivity (mean chromatid break/cell >1.02, designated as bleomycin sensitive, BS) predicted poor disease specific survival (DSS) and overall survival (OS). The 6 years DSS was 27 % in patients with BS compared with 46 % in patients who didn’t exhibit the BS phenotype (p = 0.0094). The p value remained significant when adjusted (subgroup analysis) for smoking status, age (dichotomized at 60 years), radiation doses (50–55 GY, 55–65 GY, >65 GY). The 6 years OS was 19 % for patients with BS and 29 % for patients without BS (p = 0.0193). There was a trend toward worse local regional control and worse disease free survival among patients with BS (p = 0.0972 and 0.1813 respectively). There was no difference between two groups in distant metastasis free survival (p = 0.7695). To explore the predictive value of BS in treatment related complications, we analyzed the correlation between bleomycin sensitivity values with the toxicity grades of common treatment related complications including esophagitis, pneumonitis, and lung fibrosis. However, there was no significant correlation between BS and the treatment related complications when the side effects were analyzed individually or combined. BS correlated with poor overall survival and disease specific survival in these patients with stage III non-small cell lung carcinoma treated with chemo/radiotherapy. There was also a trend indicating poor local regional control and poor disease free survival with BS. There was no significant correlation between BS and treatment related complications. BS may function as a biomarker for poor clinical outcome for this group of patients. These data suggested the hypothesis that BS may indicate a genetic instability of cancer that contributes to high tumor grade, high genetic heterogeneity, and possible treatment resistance

Shining light on single-strand lesions caused by the chemotherapy drug bleomycin

Detecting DNA Repair Capacity of Peripheral Lymphocytes from Cancer Patients with UVC Challenge Test and Bleomycin Challenge Test

A novel fluorometric oligonucleotide assay to measure O( 6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase

Heterogeneous Formation of DNA Double-Strand Breaks and Cell-Free DNA in Leukemia T-Cell Line and Human Peripheral Blood Mononuclear Cells in Response to Topoisomerase II Inhibitors

Defective Repair of DNA Single- and Double-Strand Breaks in the Bleomycin- and X-ray-sensitive Chinese Hamster Ovary Cell Mutant, BLM-2.

[Correlation of Initial DNA Damage Detected by Alkaline Comet Assay and Clinical Endpoints in Lung Cancer Patients].

Survival of Cells with Bleomycin-Induced Chromosomal Lesions in the Cultured Lymphocytes of Lung Cancer Patients

Comparative analysis of chlorambucil-induced DNA lesion formation and repair in a spectrum of different human cell systems

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response

Development of a rapid, small-scale DNA repair assay for use on clinical samples

Abstract B033: Direct and sensitive in-situ detection of DNA breaks by STRIDE and its potential as a new biomarker

Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment

In vitro cellular radiosensitivity in relationship to late normal tissue reactions in breast cancer patients: a multi-endpoint case-control study

A multi-biomarker micronucleus assay using imaging flow cytometry

Flow cytometric assessment of DNA double-strand break and repair kinetics in prediction of intrinsic radiosensitivity

Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging

A multiplexed bioluminescent reporter for sensitive and non-invasive tracking of DNA double strand break repair dynamics in vitro and in vivo

Mutagen Sensitivity Predicts Poor Overall and Disease Specific Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Chemo/radiotherapy

An ATMND/SGI based three-way junction ratiometric fluorescence probe for rapid and sensitive detection of bleomycin

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

Bleomycin-induced chromosomal aberrations in Epstein-Barr virus-transformed human lymphoblastoid cells